Shots:
- The approval is based on DIAMOND-AF trial assessing the safety and efficacy of the DTA system vs contact force-sensing ablation system in 482 patients with recurrent, symptomatic, PAF whose condition is unresponsive to drug therapy
- Results: patient complication rate (96.7% vs 93.4%); primary effectiveness (79.1% vs 75.7%); procedural efficiencies with shorter total RF times, individual RF ablation duration and reduction in volume of infused saline
- The DTA system is the 1st FDA-approved, temperature-controlled, irrigated RF ablation system with diamonds currently available to deliver ablations
Click here to read full press release/ article | Ref: PRNewswire | Image: Mission Statement Academy
The post Medtronic Receives the US FDA’s Approval for DiamondTemp Ablation System to Treat Atrial Fibrillation first appeared on PharmaShots.
